Traders should watch for closing conditions including Theravance shareholder vote and regulatory approvals, expected in H2 2026. The accretive nature and non-dilutive financing suggest potential upside; monitor YUPELRI sales trends and the $100M milestone in Q1 2027.
Price Chart
Executive Summary
Zymeworks Inc. (ZYME) announced an agreement to acquire Theravance Biopharma (TBPH) for $17.00 per share, or approximately $929 million in total cash consideration. The acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized LAMA for COPD maintenance treatment, which generated ~$60 million in annualized cash flow. The deal is financed via a $350 million non-recourse note from OMERS Life Sciences, $219 million of Zymeworks' cash, and Theravance's ~$360 million expected net cash, with an expected $100 million TRELEGY milestone in Q1 2027 reducing net investment. The transaction is expected to be accretive to earnings and cash flow upon closing in H2 2026.
Key Financial Metrics
Key Facts
- Total transaction value: ~$929 million cash consideration at $17.00 per share.
- YUPELRI® net sales: $266.6M in 2025 (12% YoY growth), $62.4M in Q1 2026 (7% growth).
- Financing: $350M non-recourse note from OMERS Life Sciences; $219M Zymeworks cash; Theravance expected net cash ~$360M.
- Expected $100M TRELEGY milestone from Royalty Pharma in Q1 2027.
- Share repurchase program of up to $125M authorized; $35.4M spent to date.
- Closing expected in H2 2026, subject to shareholder and regulatory approvals.
Financial Impact
Transaction value ~$929M; effective net investment reduced by roughly 50% after $100M milestone. Accretive to earnings and cash flow.
Risk Factors
- Failure to obtain shareholder or regulatory approval.
- Integration risks and potential decline in YUPELRI sales growth.
- Generic entry risk (licensed April 2039 but could be earlier).
- Execution risk on restructuring and cost synergies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $27.47 $27.50 | ▲ +0.11% | ▼ −0.87% | $25.15 (−8.45%) |
Jul 16, 2026 11w ago | Press Release | $24.19 $25.76 | ▼ −6.49% | ▼ −2.87% | $25.15 (−3.97%) |
Jun 29, 2026 13w ago | Press Release | $24.10 $22.86 | ▼ −5.15% | ▼ −4.87% | $25.15 (+4.36%) |
Jun 14, 2026 15w ago | Press Release | $23.26 $24.94 | ▲ +7.22% | ▲ +7.97% | $25.15 (+8.13%) |
May 15, 2026 20w ago | 3 | $24.43 $22.49 | ▼ −7.94% | ▼ −9.52% | $25.15 (+2.95%) |
Apr 21, 2026 23w ago | Press Release | $28.53 $24.40 | ▼ −14.48% | ▼ −17.64% | $25.15 (−11.85%) |
Apr 17, 2026 24w ago | Press Release | $27.80 $23.96 | ▼ −13.81% | ▼ −19.18% | $25.15 (−9.53%) |
Apr 16, 2026 24w ago | Press Release | $27.20 $24.57 | ▼ −9.67% | ▼ −15.48% | $25.15 (−7.54%) |
Apr 10, 2026 25w ago | 3 | $26.17 $24.03 | ▼ −8.18% | ▼ −15.91% | $25.15 (−3.90%) |
Mar 17, 2026 28w ago | Press Release | $23.45 $27.20 | ▲ +15.99% | ▲ +9.94% | $25.15 (+7.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access